Vismodegib: the proof of concept in Basal cell carcinoma. - Wikidata - awgldk - TriplyDB

Vismodegib: the proof of concept in Basal cell carcinoma.

Vismodegib: the proof of concept in Basal cell carcinoma.

http://www.wikidata.org/entity/Q33734736

about

Smoothened antagonist GDC-0449 (Vismodegib) inhibits proliferation and triggers apoptosis in colon cancer cell lines Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice.

P2860

Q33723836-F613E702-353A-4EB8-9084-C5EFC5EE9DB9 Q51000204-49B6DB79-9A9B-4AF0-B65E-F17AA17F9602

P2860

Vismodegib: the proof of concept in Basal cell carcinoma.

http://www.wikidata.org/entity/Q33734736

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Vismodegib: the proof of concept in Basal cell carcinoma.

@ast

Vismodegib: the proof of concept in Basal cell carcinoma.

@en

type

label

Vismodegib: the proof of concept in Basal cell carcinoma.

@ast

Vismodegib: the proof of concept in Basal cell carcinoma.

@en

prefLabel

Vismodegib: the proof of concept in Basal cell carcinoma.

@ast

Vismodegib: the proof of concept in Basal cell carcinoma.

@en

P1433

Q33734736-C8F055DF-9F63-4A24-98C6-B29A3B092C71

P1476

Q33734736-55B4E41A-7F9B-4F9B-BAA5-0808C3B78574

P2093

Q33734736-6FABD90A-56CE-4207-A878-4E31BC43DA0C

Q33734736-968AC62A-2C0A-4696-BF24-27CAAF3655AB

Q33734736-C9F1A811-1B30-47E0-BFB1-0ED8C3F3F217

Q33734736-E9BA2D12-143E-4AFE-BD8E-5A8E22F6D15C

P2860

Q33734736-086C9F65-2D1B-400B-8A6B-BF24D16DD2C9

Q33734736-092202EF-F2ED-4953-9E4A-95F962E57F35

Q33734736-13020382-699D-43C3-8C87-5BD7528BF90B

Q33734736-1AA58A0D-357C-4217-BB59-68C245C0B75D

Q33734736-1C21811E-4655-4A54-B5C1-95BEF2CCE8F2

Q33734736-2C658AA6-5ACB-41A8-9309-76D6C3D1C045

Q33734736-2D4AC31C-1D9C-49BA-91BF-E524DF3056DF

Q33734736-3A5880B6-2136-4E33-8E10-A7032BD27FBE

Q33734736-47523987-9BF1-47DE-B0DA-FBA593954741

Q33734736-5E4D4922-8EA1-48AB-83F0-9D83E317E1ED

P304

Q33734736-AF43BC16-8142-4C32-BC72-CF5A080FFED5

P31

Q33734736-A8068327-6577-40BE-8091-C05330D66624

P356

Q33734736-240CD5EC-BBD3-455D-B247-4A88DA103E1B

P407

Q33734736-13F96B6F-038B-4573-A67C-B0E6765D2C5F

P478

Q33734736-C7EBB23E-9B61-4ADD-A966-6402D88DA34C

P577

Q33734736-DDA4B500-614A-476A-BCC1-A451B7D3F15A

P698

Q33734736-B90CB88D-51DD-4B97-95C8-B1A4D739598E

P932

Q33734736-1EEDF565-2099-4DFA-97B6-63595C28EE56

P356

P1433

Clinical Medicine: Oncology

P1476

Vismodegib: the proof of concept in Basal cell carcinoma.

@en

P2093

Hassan Errihani

http://www.w3.org/2001/XMLSchema#string

Hind Mrabti

http://www.w3.org/2001/XMLSchema#string

Narjiss Berrada

http://www.w3.org/2001/XMLSchema#string

Siham Lkhoyali

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations affecting segment number and polarity in Drosophila

Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

The hedgehog signaling pathway in cancer.

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

Aggressive basal cell carcinoma: presentation, pathogenesis, and management.

Pharmacological background of EGFR targeting.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Basal-cell carcinoma.

Metastatic basal cell carcinoma: report of twelve cases with a review of the literature.

P304

77-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CMO.S14569

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24932107

http://www.w3.org/2001/XMLSchema#string

P932

4051803

http://www.w3.org/2001/XMLSchema#string